Crelosidenib clinical trials
Also written LY3410738.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2020
How each study uses crelosidenib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- LY3410738
- 5
Studies by the year they started
5 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Studies
Open first, then newest update. How each study uses crelosidenib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruitingPhase 1Eli Lilly and CompanyNCT04603001Written as LY3410738
- Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsActive, not recruitingPhase 1Eli Lilly and CompanyNCT04521686Written as LY3410738
- A Study Comparing Different Formulations of LY3410738 in Healthy Adult ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06181084Written as LY3410738
- A Study of LY3410738 in Healthy Adult ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT06181045Written as LY3410738
- Study of the Effects of Itraconazole and Carbamazepine on LY3410738 in Healthy ParticipantsTerminatedPhase 1Eli Lilly and CompanyNCT05205447Written as LY3410738
Codes
What other systems call crelosidenib · ClinicalTrials.gg INT015959
- UNII (FDA) A4DU555RMDCRELOSIDENIBOne source FDA
- NCI Thesaurus C175542CrelosidenibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | A4DU555RMD | CRELOSIDENIB | One source FDA |
| NCI Thesaurus | C175542 | Crelosidenib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.